Merkel C, Sacerdoti D, Finucci G F, Zuin R, Bazzerla G, Bolognesi M, Gatta A
Br J Clin Pharmacol. 1986 Jun;21(6):713-9. doi: 10.1111/j.1365-2125.1986.tb05237.x.
Beta-adrenoceptor blockers used in the medical management of portal hypertension decrease liver blood flow. The sporadic onset of hepatic encephalopathy during propranolol treatment was ascribed to this decrease. The aim of the present study was to evaluate the effect of chronic treatment with nadolol on liver blood flow and liver function. Nadolol, a non-cardioselective beta-adrenoceptor blocker, has been reported to be as powerful as propranolol in decreasing portal pressure. Before and after 1 month of treatment with nadolol at a dose reducing heart rate by 25%, in 15 cirrhotic patients with portal hypertension, the following parameters were determined: hepatic venous pressure gradient, hepatic blood flow, galactose eliminating capacity, aminopyrine metabolic activity, ICG clearance and intrinsic hepatic clearance. Hepatic venous pressure gradient and hepatic blood flow were decreased by nadolol. However liver function was not affected by the drug. We conclude that, despite a lowered hepatic blood flow, liver function is not affected by 1 month of nadolol treatment.
用于门静脉高压症药物治疗的β-肾上腺素能受体阻滞剂会减少肝血流量。普萘洛尔治疗期间肝性脑病的散发性发作归因于这种减少。本研究的目的是评估纳多洛尔长期治疗对肝血流量和肝功能的影响。纳多洛尔是一种非心脏选择性β-肾上腺素能受体阻滞剂，据报道在降低门静脉压力方面与普萘洛尔一样有效。在15例门静脉高压症肝硬化患者中，使用能使心率降低25%的剂量的纳多洛尔治疗1个月前后，测定了以下参数：肝静脉压力梯度、肝血流量、半乳糖清除能力、氨基比林代谢活性、吲哚菁绿清除率和肝内在清除率。纳多洛尔降低了肝静脉压力梯度和肝血流量。然而，该药物并未影响肝功能。我们得出结论，尽管肝血流量降低，但1个月的纳多洛尔治疗并未影响肝功能。
